IronOak Wealth LLC. Invests $922,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

IronOak Wealth LLC. bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 38,122 shares of the company's stock, valued at approximately $922,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Crewe Advisors LLC purchased a new stake in Hims & Hers Health during the 4th quarter valued at $28,000. Blume Capital Management Inc. increased its stake in Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 600 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after acquiring an additional 1,413 shares during the period. Summit Securities Group LLC purchased a new position in Hims & Hers Health during the 4th quarter valued at $38,000. Finally, US Bancorp DE grew its stake in Hims & Hers Health by 346.7% in the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock worth $47,000 after acquiring an additional 1,508 shares in the last quarter. Institutional investors own 63.52% of the company's stock.

Analyst Upgrades and Downgrades

HIMS has been the topic of several research reports. Wall Street Zen raised shares of Hims & Hers Health from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Piper Sandler reaffirmed a "neutral" rating and set a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Bank of America upped their price target on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a report on Tuesday, April 29th. UBS Group reaffirmed a "mixed" rating on shares of Hims & Hers Health in a report on Tuesday, May 6th. Finally, Citigroup reaffirmed a "sell" rating and issued a $30.00 price target (up from $25.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $37.67.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded up $4.34 during midday trading on Friday, reaching $56.74. 40,831,840 shares of the stock were exchanged, compared to its average volume of 19,734,873. The stock has a market capitalization of $12.70 billion, a P/E ratio of 128.96 and a beta of 1.84. The company has a 50 day simple moving average of $39.45 and a 200 day simple moving average of $35.80. Hims & Hers Health, Inc. has a twelve month low of $13.47 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. During the same quarter last year, the firm earned $0.05 earnings per share. The firm's quarterly revenue was up 110.7% compared to the same quarter last year. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Irene Becklund sold 2,203 shares of the firm's stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total value of $63,402.34. Following the sale, the insider now directly owns 8,007 shares in the company, valued at $230,441.46. This trade represents a 21.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Soleil Boughton sold 4,151 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $45.14, for a total value of $187,376.14. Following the completion of the transaction, the insider now owns 166,134 shares in the company, valued at approximately $7,499,288.76. The trade was a 2.44% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 609,937 shares of company stock worth $24,801,703. Company insiders own 13.71% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.